Biomarin Pharmaceutical Inc (BMRN)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	595,138	594,627	594,116	593,605	593,095	592,586	1,084,990	1,084,010	1,083,020	1,082,030	1,081,050	1,080,060	1,079,080	1,078,090	1,077,110	1,076,130	1,075,140	1,074,160	1,073,200	486,713
Total stockholders’ equity	US$ in thousands	5,657,990	5,413,400	5,286,300	5,073,820	4,951,550	4,896,900	4,782,830	4,659,040	4,603,160	4,568,510	4,499,740	4,386,240	4,265,670	4,261,080	4,236,500	4,162,010	4,100,930	4,053,890	3,236,680	3,239,960
Debt-to-capital ratio		0.10	0.10	0.10	0.10	0.11	0.11	0.18	0.19	0.19	0.19	0.19	0.20	0.20	0.20	0.20	0.21	0.21	0.21	0.25	0.13

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $595,138K ÷ ($595,138K + $5,657,990K)
= 0.10

The debt-to-capital ratio of Biomarin Pharmaceutical Inc has shown a consistent downward trend over the past few years, indicating a decreasing reliance on debt to fund its operations and growth. As of December 31, 2024, the debt-to-capital ratio stood at 0.10, demonstrating that only 10% of the company's capital structure is funded by debt, while the remaining 90% is attributable to equity. This suggests a strong financial position and a lower financial risk, as a lower debt-to-capital ratio typically signifies lower financial leverage and greater financial stability. The company's ability to maintain a decreasing debt-to-capital ratio reflects prudent financial management and a conservative approach to borrowing, which bodes well for its long-term financial health and sustainability.